Not checkedNot checked for notices yet.
Reply to ‘Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?’
Assad Shiti, Idit Goldfracht, Naim Shaheen and 2 more
Nature Communications · 2021
doi:10.1038/s41467-021-21950-6 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
In our recent report 1 , we combined developmental biology-inspired differentiation strategies of human pluripotent stem cells (hPSCs) to derive chamber-specific cardiomyocytes 2 and a collagen-hydrogel-based tissue engineering strategy 3 to generate ring-shaped ventricular and atrial-specific engineered heart tissues (EHTs). Detailed molecular, ultrastructural, and functional phenotyping, together with targeted pharmacology, confirmed the chamber-specific identity of the atrial/ventricular EHTs, and demonstrated the potential of these models for disease modeling and drug testing applications. The latter included the ability to induce reentrant arrhythmias in the atrial EHTs and the ability to terminate such arrhythmias with established anti-arrhythmic agents (flecainide and vernakalant). In the accompanying comment, Christ et al. 4 raise concerns with regards to the relative immature properties of the chamber-specific EHTs and their different response to some of the anti-arrhythmic drugs tested (vernakalant and lidocaine) in comparison to their reported effects in adult human atrial and ventricular heart tissues.
Abstract licence: CC BY-NC-ND
References19
- 6.
- 13.
- 15.
- 16.
15 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.